Patients who are unable to reliably tolerate and/or receive oral medications
36.0
Inability to take oral medications on a continuous basis
276.0
Participants must be able to take oral medications
90.0
Inability to swallow oral medications
90.0
Able to swallow and retain oral medication (note: for patients unable to swallow tablets, an oral suspension preparation is acceptable)
143.0
Patients must have the ability to swallow oral medication
491.0
Ability to swallow liquids
68.0
Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow, retain, and/or absorb the drug are excluded
70.0
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
1500.0
Able to swallow and retain oral medication
44.0
Ability to swallow oral medications
57.0
Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel* Active peptic ulcer disease* Malabsorption syndrome
340.0
Patients must be able to swallow oral medications
23.0
Patients must be able to swallow medication by oral route
223.0
Ability to take oral medications
66.0
Ability to swallow oral medications
209.0
Ability to swallow medication
30.0
Ability to swallow oral medications
30.0
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
549.0
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
680.0
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
126.0
Patients must have the ability to swallow oral dosage forms
50.0
Patients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligible
180.0
Ability to swallow oral medications
32.0
Able to take oral medication and has no history of gastric surgery or pathology
64.0
Patient is unable to swallow or keep down oral medication
48.0
CLINICAL/LABORATORY CRITERIA: Patients must be able to swallow oral medications and must not have a gastro-intestinal disorder with diarrhea as a major symptom or that may alter absorption such as malabsorption syndromes or gastric resection
53.0
Ability to swallow and retain oral medication
147.0
Patients must have the ability to swallow and retain oral medication
348.0
Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded
24.0
Subject is able to swallow and retain oral medication and does not have uncontrolled emesis or gastrointestinal disorders likely to interfere with absorption of the study medication
72.0
Patients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
90.0
Ability to swallow and retain oral medication
132.0
Patients that unable to swallow oral medications are ineligible
21.0
